Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Reservoir Media, Inc. has made available a formal investor presentation on its website and filed it as an exhibit to this 8-K. The presentation, dated November 2026, provides updates on the company's business strategy, growth initiatives, and market opportunities for investors.
Greenland Technologies received a deficiency notice from Nasdaq because its Class A ordinary shares closed below the $1.00 minimum bid price for 30 consecutive business days. The company has 180 calendar days, until May 10, 2027, to regain compliance by maintaining a $1.00 share price for at least 10 consecutive business days. The company is considering options to cure the deficiency, including a potential share consolidation (reverse stock split).
Life Time Group Holdings Director Green LTF Holdings II LP Sells $78.9M of Stock
Green LTF Holdings II LP, Director, sold 1,683,651 shares of Life Time Group Holdings, Inc. at $46.86 a share, worth $78.9M in total on Nov 10, 2026. Shares held after the trade: 0 (-100.0%).
High Roller Technologies reported Q3 2026 financial results and highlighted the commercial launch of its ROLR prediction markets platform on October 21. The company ended the quarter with $13.4 million in cash and no debt, noting that revenue per depositing casino customer more than doubled year-over-year despite lower overall casino revenue due to market exits.
Term
Q3 2026
“On October 21, our ROLR prediction markets platform went live to the public, and High Roller formally entered its next chapter. The ROLR iOS app launched in the Apple App Store on November 9, and we plan to release our Android app in Q4 2026. We believe prediction markets have the potential to become the major growth driver for High Roller in 2027.”
Seth Young, Chief Executive Officer of High Roller Technologies
“Our Q3 2026 results reflect lower online casino revenue due to the year-over-year impact of having exited certain markets in 2025, as well as our continued investment to bring ROLR to market. The casino customers we serve today are more valuable, with revenue per depositing customer more than doubling year over year. We ended the quarter with $13.4 million in cash and cash equivalents and no outstanding borrowings, which we believe is sufficient to fund our operations for at least the next twelve months.”
Adam Felman, Chief Financial Officer of High Roller Technologies
Honeywell Aerospace Inc. announced it expects to hold its 2027 Annual Meeting of Shareholders on or about May 12, 2027. Because the company did not hold an annual meeting in 2026, it has established new deadlines for shareholder proposals and director nominations, with Rule 14a-8 proposals due by December 11, 2026.
Broadway Financial Corporation reported Q3 2026 net income attributable to common stockholders of $392 thousand, or $0.04 per diluted share, showing improvement over the prior quarter. The results were driven by strong loan growth of 11.4% and deposit growth of 21.0% during the first nine months of the year. CEO Brian Argrett highlighted the disciplined execution of strategic priorities and stable credit quality despite an evolving economic environment.
Term
Q3 2026
“Our third-quarter results reflect disciplined execution of our strategic priorities, resulting in strong growth in both loans and deposits while maintaining solid capital levels. We continue to operate with a disciplined approach to risk management and underwriting as we navigate an evolving economic environment.”
Delcath Systems Director Bridget A. Martell Sells $489K of Stock
Bridget A. Martell, Director, sold 22,500 shares of Delcath Systems, Inc. at $21.66 to $22.26 a share (average $21.71) in 2 transactions, worth $489K in total on Nov 12, 2026. Shares held after the trade: 0 (-100.0%).
Transportation and Logistics Systems, Inc. reported a total shareholders' deficit of $21,999,597 as of September 30, 2026, with its primary operations classified as discontinued. The company faces significant liquidity challenges, including $7.2 million in liabilities from discontinued operations and a need for substantial additional financing to fund ongoing losses.
TPG RE Finance Trust Director Michael Gillmore Buys $16.2K of Stock
Michael Gillmore, Director, bought 2,500 shares of TPG RE Finance Trust, Inc. at $6.50 a share, worth $16.2K in total on Nov 12, 2026. Shares held after the trade: 5,000 (+100.0%).
TPG RE Finance Trust Director Michael Bradley Smith Buys $64.6K of Stock
Michael Bradley Smith, Director, bought 10,000 shares of TPG RE Finance Trust, Inc. at $6.45 to $6.47 a share (average $6.46) in 2 transactions, worth $64.6K in total between Nov 11, 2026 and Nov 12, 2026. Shares held after the trade: 115,223 (+4.5%).
C4 Therapeutics CFO Kendra Adams Sells $122K of Stock
Kendra Adams, CFO, sold 45,173 shares of C4 Therapeutics, Inc. at $2.71 a share, worth $122K in total on Nov 12, 2026. Shares held after the trade: 337,150 (-11.8%).
Life Time Group Holdings Director John G. Danhakl Sells $78.9M of Stock
John G. Danhakl, Director, sold 1,683,651 shares of Life Time Group Holdings, Inc. at $46.86 a share, worth $78.9M in total on Nov 10, 2026. Shares held after the trade: 491,915 (-77.4%).
James O. Morton will retire from the Boards of Directors of Independent Bank Corp. and Rockland Trust Company effective November 15, 2026. His retirement is in accordance with the company's Governance Principles, which require directors to retire upon reaching the age of 72. Following his departure, the board size will be reduced from 14 to 13 members.
Bandwidth Insider Douglas A. Suriano Sells $177K of Stock
Douglas A. Suriano sold 3,800 shares of Bandwidth Inc. at $46.21 to $47.11 a share (average $46.52) in 2 transactions, worth $177K in total on Nov 12, 2026. Shares held after the trade: 41,610 (-3.0%).
Vaxcyte Chief Technical Ops Officer Harpreet S. Dhaliwal Sells $1.15M of Stock
Harpreet S. Dhaliwal, Chief Technical Ops Officer, sold 17,000 shares of Vaxcyte, Inc. at $67.33 to $68.82 a share (average $67.83) in 3 transactions, worth $1.15M in total on Nov 11, 2026. Shares held after the trade: 68,085 (-0.8%).
TaoWeave, Inc. reported its Q3 2026 results, highlighting significant activity in its Digital Assets segment, including unrealized gains from revaluations and realized gains from asset sales. The company also managed complex equity transactions involving Series F Preferred Stock and various warrant exercises, while maintaining distinct reporting for its Managed Services and Collaboration Products segments.
TherapeuticsMD reported net income of $0.49 million for the quarter ended September 30, 2026, compared to $0.15 million in the prior year period, driven by increased license revenue from its royalty-based business model. The company maintained a stable balance sheet with $10.4 million in cash and total stockholders' equity of $27.6 million.
IEH Corporation reported record financial results for its second fiscal quarter ended September 30, 2026, with revenue increasing 51% year-over-year to $10.7 million. The company achieved a record backlog exceeding $56 million and returned to profitability with net income of $1.36 million compared to a net loss in the prior year period.
Term
Q2 2027
“As great as this year’s first quarter was, the second quarter exceeded it by every measure. The first quarter’s record revenue of $10 million was eclipsed by this quarter’s $10.7 million. Similarly, our operating profit increased 57%, and our net income and earnings per share both more than doubled.”
Dave Offerman, President and CEO of IEH Corporation
“We shattered our previous backlog record by 40%, and we continue to hire and add capacity and equipment to meet the surge in demand in the defense, commercial aerospace, space and medical markets we serve.”
Dave Offerman, President and CEO of IEH Corporation
Incyte Corporation has decided not to proceed with its planned Phase 3 MAESTRA-3 study of INCB123667 in combination with bevacizumab for ovarian cancer. The decision was based on internal portfolio prioritization rather than safety or efficacy concerns and is not expected to impact the company's financial guidance.
Silvaco Group Insider Candace Jackson Sells $22.4K of Stock
Candace Jackson sold 3,000 shares of Silvaco Group, Inc. at $7.45 a share, worth $22.4K in total on Nov 12, 2026. Shares held after the trade: 41,722 (-6.7%).
Seneca Bancorp, Inc. reported a net income of $129,000 for the nine months ended September 30, 2026, compared to $137,000 in the prior year period. While net interest income increased significantly to $7.7 million, the results were impacted by higher noninterest expenses, including a $262,000 impairment of long-lived assets and increased compensation costs.
Boston Omaha Corporation reported total revenues of $22.2 million for the third quarter of 2026, a slight increase from $21.9 million in the prior year. The company recorded a net loss attributable to common stockholders of $0.2 million for the quarter, an improvement from a $2.6 million loss in Q3 2025, primarily driven by equity in income of unconsolidated affiliates and income from discontinued operations.
Prospect Floating Rate & Alternative Income Fund, Inc. reported total investment income of $2.05 million for the quarter ended September 30, 2026, a slight decrease from $2.19 million in the prior year period. Net assets increased to $38.01 million from $37.10 million at fiscal year-end, while the net asset value per share for Class A and Class I shares decreased slightly to $3.88.
Curis, Inc. reported a total stockholders' equity of $2.55 million as of September 30, 2026, a decrease from $5.46 million at the end of 2025. The company continues to incur substantial losses, with an accumulated deficit reaching $1.29 billion, and management has identified conditions that raise substantial doubt about its ability to continue as a going concern.
Lisata Therapeutics reported a significant increase in total assets to $648.4 million following the acquisition of Marea, which added $292.9 million in intangible assets and $64.7 million in goodwill. The company recorded a net loss of $6.8 million for the third quarter of 2026, with research and development expenses increasing to $5.2 million as they advance their combined pipeline.
Science Applications International $500M Debt Financing with Truist Bank
Science Applications International Corporation (SAIC) closed a private offering of $500 million in 6.750% Senior Notes due 2034. The company used the net proceeds of approximately $493 million to redeem its outstanding 4.875% Senior Notes due 2028 and for general corporate purposes.
For the three months ended September 30, 2026, OptimizeRx reported net revenue of $21.6 million and net income of $1.2 million, compared to $26.1 million and $0.8 million in the prior year period. While quarterly profitability improved, the company recorded a slight net loss of $3,000 for the nine-month period as revenues declined from $77.2 million to $62.0 million year-over-year.
Vistagen reported financial results for its fiscal year 2027 second quarter ended September 30, 2026, and provided a corporate update on its fasedienol Phase 3 development plan for social anxiety disorder. The company highlighted constructive FDA feedback regarding its clinical trial design and the appointment of Dr. Douglas J. Williamson to its Board of Directors. Vistagen also implemented cost-management initiatives to prioritize capital for its late-stage neuroscience programs.
Term
Q2 2027
“Following our recent productive meeting with the FDA and our evaluation of the extensive body of efficacy, safety, and patient experience data generated throughout Phase 2 and Phase 3 development of fasedienol, we believe we have clarity on the potential regulatory pathways forward for fasedienol in social anxiety disorder”
Shawn Singh, President and Chief Executive Officer of Vistagen
“Recent alignment of our operating structure and capital resources with our late-stage development opportunities in both social anxiety disorder and menopausal hot flashes, position us to execute our plan to advance these programs while maintaining flexibility to create long-term shareholder value.”
Shawn Singh, President and Chief Executive Officer of Vistagen
Werewolf Therapeutics is currently pursuing a merger with Ambros and a concurrent PIPE financing to address substantial doubt about its ability to continue as a going concern. As of November 9, 2026, the company had 48,599,066 shares of common stock outstanding and is evaluating strategies to raise additional capital to fund its research and development programs.
Inhibrx Biosciences reported Q3 2026 financial results, highlighting a cash position of $199.5 million and $2.0 million in revenue from a licensing agreement with Pfizer. The company is advancing its clinical pipeline, with upcoming data presentations for ozekibart in Ewing sarcoma and ongoing enrollment in the Phase 2 HexAgon study for ordastobart.